Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma-Reference-Cited by-同舟云学术

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

Published:2022-11-05 Issue:1 Volume:37 Page:154-163
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Alarcon Tomas Ana^ORCID,Fein Joshua A.^ORCID,Fried Shalev^ORCID,Flynn Jessica R.,Devlin Sean M.,Fingrut Warren B.,Anagnostou Theodora,Alperovich Anna,Shah Nishi,Fraint Ellen^ORCID,Lin Richard J.^ORCID,Scordo Michael,Batlevi Connie Lee^ORCID,Besser Michal J.,Dahi Parastoo B.^ORCID,Danylesko Ivetta,Giralt Sergio^ORCID,Imber Brandon S.,Jacoby Elad^ORCID,Kedmi Meirav,Nagler Arnon,Palomba M. Lia^ORCID,Roshal Mikhail,Salles Gilles A.,Sauter Craig,Shem-Tov Noga,Shimoni Avichai^ORCID,Yahalom Joachim,Yerushalmi Ronit,Shah Gunjan L.^ORCID,Avigdor Abraham,Perales Miguel-Angel^ORCID,Shouval Roni^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01739-2.pdf

Reference43 articles.

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.

2. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.

3. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.

4. Sauter CS, Senechal B, Riviere I, Ni A, Bernal Y, Wang X, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134:626–35.

5. Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19 + relapsed/refractory malignancies. Mol Ther. 2021;29:636–44.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

3. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration;Cancer Medicine;2024-09

4. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

5. Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments;Cureus;2024-08-06